TY - JOUR
T1 - Healthcare costs in relation to kidney function among older people
T2 - the SCOPE study
AU - the Screening for CKD among Older People across Europe (SCOPE) study investigators
AU - Balducci, Francesco
AU - Di Rosa, Mirko
AU - Roller-Wirnsberger, Regina
AU - Wirnsberger, Gerhard
AU - Mattace-Raso, Francesco
AU - Tap, Lisanne
AU - Formiga, Francesc
AU - Moreno-González, Rafael
AU - Kostka, Tomasz
AU - Guligowska, Agnieszka
AU - Artzi-Medvedik, Rada
AU - Melzer, Itshak
AU - Weingart, Christian
AU - Sieber, Cornel
AU - Ärnlöv, Johan
AU - Carlsson, Axel C.
AU - Lattanzio, Fabrizia
AU - Corsonello, Andrea
AU - Fabbietti, Paolo
AU - Nacciariti, Moreno
AU - Firmani, Romano
AU - D’Alia, Sonia
AU - Guarasci, Francesco
AU - Cozza, Annalisa
AU - Garasto, Sabrina
AU - Postacchini, Demetrio
AU - Giuli, Cinzia
AU - Giacconi, Robertina
AU - Provinciali, Mauro
AU - Bordoni, Enrico
AU - Della Bella, Stefano
AU - Lenci, Federica
AU - Galeazzi, Roberta
AU - Bonfigli, Anna Rita
AU - Giammarchi, Cinzia
AU - Di Stefano, Giuseppina
AU - Moresi, Raffaella
AU - D’Ascoli, Paola
AU - Bolognini, Silvia
AU - Bustacchini, Silvia
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2025/2/1
Y1 - 2025/2/1
N2 - Purpose: In this study, a comprehensive analysis of costs of chronic kidney disease (CKD) was performed, to understand factors associated with the economic burden of the disease in a multicentre international framework. Methods: The impact on costs of demographics, socio-economics, clinical, and functional variables was tested in 2204 subjects aged 75 years or more attending outpatient clinics in Europe using a multicentre 2-year prospective cohort study. By means of collected resources consumption and unit cost data a comprehensive cost database was built and then investigated using multilevel regression modeling. Results: Overall, hospitalization, medications and specialist visits were the main cost items, with a notable variability among countries. Estimated yearly costs were 4478€ ± 9804€, rising up to 6683€ ± 10,953€ for subjects with estimated Glomerular Filtration Rate (eGFR) < 30. Costs increased significantly according to the severity of the disease, gender and age. Clinical and functional covariates were also significantly associated with CKD-related total costs, even after correcting for the inter-country variability. Conclusion: Findings corroborate the importance of multidimensional assessment of participants with CKD, as multimorbidity and functional disability produce a detrimental impact on participant’s prognosis and cost of care. Preservation of functional impairment and adequate management of comorbidities may thus help decreasing the overall consumption on health care resources in CKD patients, especially in older people.
AB - Purpose: In this study, a comprehensive analysis of costs of chronic kidney disease (CKD) was performed, to understand factors associated with the economic burden of the disease in a multicentre international framework. Methods: The impact on costs of demographics, socio-economics, clinical, and functional variables was tested in 2204 subjects aged 75 years or more attending outpatient clinics in Europe using a multicentre 2-year prospective cohort study. By means of collected resources consumption and unit cost data a comprehensive cost database was built and then investigated using multilevel regression modeling. Results: Overall, hospitalization, medications and specialist visits were the main cost items, with a notable variability among countries. Estimated yearly costs were 4478€ ± 9804€, rising up to 6683€ ± 10,953€ for subjects with estimated Glomerular Filtration Rate (eGFR) < 30. Costs increased significantly according to the severity of the disease, gender and age. Clinical and functional covariates were also significantly associated with CKD-related total costs, even after correcting for the inter-country variability. Conclusion: Findings corroborate the importance of multidimensional assessment of participants with CKD, as multimorbidity and functional disability produce a detrimental impact on participant’s prognosis and cost of care. Preservation of functional impairment and adequate management of comorbidities may thus help decreasing the overall consumption on health care resources in CKD patients, especially in older people.
KW - Chronic kidney disease
KW - Healthcare costs
KW - Multicentre
KW - Older people
KW - Resources consumption
UR - http://www.scopus.com/inward/record.url?scp=85208933483&partnerID=8YFLogxK
U2 - 10.1007/s41999-024-01086-8
DO - 10.1007/s41999-024-01086-8
M3 - Article
C2 - 39535723
AN - SCOPUS:85208933483
SN - 1878-7649
VL - 16
SP - 135
EP - 148
JO - European Geriatric Medicine
JF - European Geriatric Medicine
IS - 1
M1 - e0158765
ER -